Triazole antifungals repurposed for antibiotic-resistant
This patent covers a new use for existing triazole antifungal drugs — the same class of medications used to treat fungal infections like thrush — to kill Neisseria bacteria, including gonorrhea and bacterial meningitis. The core discovery is that these already-approved or well-studied compounds have antibacterial activity against a genus of pathogens that has become dangerously resistant to conventional antibiotics. Because triazoles already have known safety profiles in humans, the path to clinical use could be shorter than developing an entirely new antibiotic. The approach may also open combination therapy options alongside existing antibacterials.
What you could build
A repurposed triazole-based therapeutic (oral or topical) indicated for gonorrhea or meningococcal infection, sold to hospital systems, sexual health clinics, and public health agencies; a pharmaceutical company with an existing triazole franchise would be the most natural licensor.
Who in Virginia should care
Northern Virginia-based federal health agencies (HHS, NIH, BARDA) and defense health contractors focused on antibiotic-resistant STIs as a military readiness issue would be natural partners or funders.
Readiness: Concept
Concept — described but not yet demonstrated. Lab validated — supported by experimental results in the patent. Prototype likely — the text describes a built, working embodiment.
Readiness is inferred from the patent text, not from a lab visit.
The record
- Inventors
- Mohamed SELEEM
- Filed
- Patent pending — filed October 29, 2024
- Status
- Application
- Publication number
- US20250281464A1
Ready to talk?
Virginia Tech Intellectual Properties handles licensing for this technology.
Prosim summaries are generated from public patent text and are not legal advice.